Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group
Background Sorafenib is an oral small molecule inhibitor of multiple kinases controlling tumor growth and angiogenesis. The purpose of the phase 2 study was to determine the response rate of sorafenib and gain further information on the associated toxicities, pharmacokinetics, and pharmacodynamics o...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artigo |
| Language: | English |
| Published: |
2015
|
| Online Access: | https://doi.org/10.1002/pbc.25548 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|